Cetera Investment Advisers
HUMA icon

Cetera Investment Advisers’s Humacyte HUMA Stock Holding History

Cetera Investment Advisers’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.3K Buy
106,711
+49,404
+86% +$45.8K ﹤0.01% 4695
2026
Q1 		$34.8K Sell
57,307
-10,825
-16% -$11.3K ﹤0.01% 4619
2025
Q4 		$65.4K Sell
68,132
-2,400
-3% -$3.4K ﹤0.01% 4473
2025
Q3 		$123K Buy
70,532
+38,300
+119% +$75K ﹤0.01% 4286
2025
Q2 		$67.4K Buy
32,232
+3,952
+14% +$7.59K ﹤0.01% 3940
2025
Q1 		$48.2K Buy
28,280
+400
+1% +$1.5K ﹤0.01% 3863
2024
Q4 		$141K Buy
27,880
+9,134
+49% +$45.2K ﹤0.01% 3514
2024
Q3 		$102K Buy
18,746
+3,035
+19% +$20K ﹤0.01% 3535
2024
Q2 		$75.4K Buy
15,711
+5,446
+53% +$28.3K ﹤0.01% 3562
2024
Q1 		$31.9K Buy
+10,265
New +$34.5K ﹤0.01% 3606

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cetera Investment Advisers's HUMA Position: Q2 2026 in Review

Cetera Investment Advisers increased its Humacyte (HUMA) stake by 86% in Q2 2026, buying an estimated $45.8K and bringing the position to 106,711 shares worth $83.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4695.

Cetera Investment Advisers first reported a position in HUMA in Q1 2024 and has held it in 10 quarters since. The position peaked at $141K in Q4 2024. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Cetera Investment Advisers held 106,711 shares of Humacyte worth $83.3K as of Q2 2026.
  • Cetera Investment Advisers bought 49,404 Humacyte shares in Q2 2026, an estimated $45.8K.
  • Humacyte made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #4695 holding.
  • Cetera Investment Advisers first reported a position in Humacyte in Q1 2024 and has held it in 10 quarters since.
  • Cetera Investment Advisers's Humacyte position peaked at $141K in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.